UPDATE: Piper Jaffray Raises PT to $27 on Pacira Pharmaceuticals on Strong Exparel Data Points
January 28, 2013 at 13:59 PM EST
Piper Jaffray reiterated its Overweight rating on Pacira Pharmaceuticals (NASDAQ: PCRX ) and raised the price target from $22.00 to $27.00. Piper Jaffray noted, “Data points for Pacira's Exparel continue to look favorable, reinforcing our confidence in a strong sales ramp for 2013 and beyond. Institutional sales (wholesale acquisition cost
